MRC1 and hyperinsulinemic hypoglycemia, familial, 4: Furthermore, MMR dysfunction either MMR deficiency by immunohistochemistry or MSI-high is one prognostic factor and indicates candidates for novel treatments with immune checkpoint inhibitors (Green et al., 2020).